Clinical Trial Update: AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing osimertinib (AZD9291) versus platinum-based doublet chemotherapy in locally advanced or metastatic non-small cell lung cancer has comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: AstraZeneca | Conditions: Anticancer Treatment | Phase 3 | Status: COMPLETED | Results posted: 2017-07-21